SciSparc logo

SciSparc(NASDAQ) SPRC

Market Cap$739.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-96%
1 Month-75%
$0.81
-37.30%
-0.48Today
SciSparc last closing stock price
MetricPriceDate
Last closeUSD 1.292026-10-26
SciSparc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.86%USD 1.402026-10-19
1 month-75.24%USD 5.212026-09-25
3 month-75.8%USD 5.332026-07-28
Year to date-89.46%USD 12.242025-12-31
1 year-96.43%USD 36.182025-10-24
3 year-99.8%USD 653.942023-10-27
5 year-100%USD 29,484.002021-10-27
Since inception-99.99%USD 22,113.542021-08-30

SciSparc Financials at a Glance

Market Cap

$739.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.61M

Net Income (TTM)

-$20.39M

EPS (TTM)

-$79.46

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$0.81

Volume

1,071,926.047

Open

$0.86

Previous Close

$1.29

Daily Range

$0.73 - $0.95

52-Week Range

$0.73 - $34.65

Estimated Earnings Date

Jul 29, 2026

SPRC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SciSparc

SciSparc Ltd. is a pharmaceutical company focused on the clinical development of cannabinoid-derived medications. The company is advancing several drug candidates aimed at treating various medical conditions, including Tourette syndrome, pain, and autism spectrum disorder.

Products and Services
  • SCI-110 for Tourette syndrome and Alzheimer's agitation
  • SCI-160 targeting pain management
  • SCI-210 for autism spectrum disorder and epilepsy
Growth Outlook
  • Partnership with Procaps enhances development capabilities for SCI-110
  • Collaboration with Sheba Fund aims to explore SCI-210's potential
  • Phase IIa trial for SCI-110 underway at The Israeli Medical Center for Alzheimer's
Financial Highlights
  • Recent quarterly revenue of 284,000, showing potential growth
  • Gross profit margin of 74.65% indicates strong product viability
  • Cash reserves of 4.44 million support ongoing research and development
SciSparc Ltd. operates in the biotechnology sector, leveraging cannabinoid science to address unmet medical needs. The company's strategic partnerships and ongoing clinical trials position it for potential breakthroughs in therapeutic applications. Recent financial data reflects a commitment to research, with significant investments in R&D, indicating a focus on long-term growth despite current operating losses. The company's cash reserves provide a buffer for continued operations as it navigates the complexities of drug development.
AI Generated • Oct 22, 2026

Industry

Pharmaceuticals

Employees

3

CEO

Oz Adler, CPA

Headquarters

Tel Aviv, TA 6971916, IL

SPRC Financials

Key Financial Metrics (TTM)

Gross Margin

64.51%

Operating Margin

-660.53%

Net Income Margin

-1210.90%

Return on Equity

-200.93%

Return on Capital

-189.99%

Return on Assets

-44.46%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$739.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

573.20K

Volume

1.07M

Avg. Volume

1.41M

Financials (TTM)

Gross Profit

$641.00K

Operating Income

-$24.48M

EBITDA

-$16.98M

Operating Cash Flow

-$10.61M

Capital Expenditure

$1.00K

Free Cash Flow

-$10.60M

Cash & ST Invst.

$4.44M

Total Debt

$2.68M

SciSparc Performance Analysis

SciSparc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,347,000N/A
20232023-12-31USD 2,879,000113.7%
20242024-12-31USD 1,306,000-54.6%
20252025-12-31USD 856,000-34.5%
SciSparc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-44.5%
Q22025-06-30-1.1%
Q42025-12-31-14.3%
Q22026-06-30-28.1%
SciSparc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2,784.08-79.9%
20232023-12-31USD -2,372.69-14.8%
20242024-12-31USD -203.89-91.4%
20252025-12-31USD -882.64332.9%
SciSparc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3183.5%
Q22025-06-30-1177.0%
Q42025-12-3156.5%
Q22026-06-3086.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$284.00K

-66.2%

Gross Profit

$212.00K

-55.3%

Gross Margin

74.65%

N/A

Market Cap

$739.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$246.50K

N/A

Employees

3

N/A

Net Income

-$5.37M

-56.0%

EBITDA

-$4.80M

-45.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.44M

+73.3%

Total Debt

$2.68M

+4085.9%

Accounts Receivable

$7.00K

-97.8%

Inventory

$67.00K

-83.9%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$2.68M

+6950.0%

Return on Assets

-44.46%

N/A

Return on Invested Capital

-36.99%

N/A

Free Cash Flow

-$3.56M

-62.0%

Operating Cash Flow

-$3.56M

-62.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTIXProtagenic Therapeutics, Inc.
$0.65-9.99%
SCNIScinai Immunotherapeutics Ltd.
$0.53-2.12%
ONCOOnconetix, Inc.
$0.38-5.86%
SLXNSilexion Therapeutics Ltd.
$0.17-3.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$16.09+11.24%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$95.67+5.71%
EWZiShares - iShares Msci Brazil ETF
$34.63+1.39%
INTCIntel
$92.58+2.33%

Questions About SPRC

What is the current price of SciSparc?

SciSparc is trading at $0.80 per share.

What is the 52-week range for SciSparc?

Over the past 52 weeks, SciSparc has traded between $0.73 and $34.65.

How much debt does SciSparc have?

As of the most recent reporting period, SciSparc reported total debt of $366.00K.

How much cash does SciSparc have on hand?

SciSparc reported $4.61M in cash and cash equivalents in its most recent financial results.

What is SciSparc’s dividend yield?

SciSparc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.